A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Social Anxiety Disorder
Interventions
DRUG

Fasedienol Nasal Spray - Placebo Nasal Spray

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.

DRUG

Fasedienol Nasal Spray - Fasedienol Nasal Spray

Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.

DRUG

Placebo Nasal Spray - Placebo Nasal Spray

Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.

Trial Locations (5)

27511

RECRUITING

Vistagen Clinical Site, Cary

33777

RECRUITING

Vistagen Clinical Site, Largo

44130

ACTIVE_NOT_RECRUITING

Vistagen Clinical Site, Cleveland

75093

RECRUITING

Vistagen Clinical Site, Plano

08755

RECRUITING

Vistagen Clinical Site, Toms River

All Listed Sponsors
lead

VistaGen Therapeutics, Inc.

INDUSTRY